Immuneering (IMRX) Interest Expenses (2020 - 2026)
Immuneering (IMRX) posted quarterly Interest Expenses of $18.1 million for Q1 2026, up 9749.53% year-over-year from $183546.0 in Q1 2025, and up 9462.72% quarter-over-quarter from $189051.0 in Q4 2025.
Immuneering (IMRX) Interest Expenses (2020 - 2026) Analysis & Trends
Immuneering's Interest Expenses history runs 7 years deep, the most recent figure standing at $18.1 million for Q1 2026.
- In Q1 2026, Interest Expenses rose 9749.53% year-over-year to $18.1 million; the TTM figure through Mar 2026 stood at $18.1 million (up 2303.11% YoY), while the FY2025 annual figure was $73.4 million, up 24.38% from the prior year.
- Interest Expenses for Q1 2026 stood at $18.1 million, up from $189051.0 in the prior quarter.
- The five-year high for Interest Expenses was $29.5 million in Q3 2025, with the low at $129814.0 in Q4 2022.
- The 5-year median for Interest Expenses is $5.6 million (2025), against an average of $8.3 million.
- The sharpest annual moves came in 2022 and 2023: Interest Expenses surged 18981.34% in 2022, then sank 95.9% in 2023.
- Immuneering's Interest Expenses stood at $129814.0 in 2022, then jumped by 48.37% to $192600.0 in 2023, then decreased by 4.7% to $183546.0 in 2024, then gained by 3.0% to $189051.0 in 2025, then jumped by 9462.72% to $18.1 million in 2026.
- Business Quant data shows IMRX's Interest Expenses at $18.1 million in Q1 2026, $189051.0 in Q4 2025, and $29.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Immuneering | 327.37 Mn | 327.37 Mn | - | 15.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.21 Mn |
| Jun 30, 2026 | 15.21 Mn |
| Mar 31, 2026 | 18.08 Mn |
| Mar 31, 2026 | 18.08 Mn |
| Dec 31, 2025 | 189,051.00 |
| Dec 31, 2025 | 189,051.00 |
| Sep 30, 2025 | 29.54 Mn |
| Sep 30, 2025 | 29.54 Mn |
| Jun 30, 2025 | 5.60 Mn |
| Jun 30, 2025 | 5.60 Mn |
| Mar 31, 2025 | 183,546.00 |
| Mar 31, 2025 | 183,546.00 |
| Dec 31, 2024 | 183,546.00 |
| Dec 31, 2024 | 183,546.00 |
| Sep 30, 2024 | 6.15 Mn |
| Sep 30, 2024 | 6.15 Mn |
| Jun 30, 2024 | 6.33 Mn |
| Jun 30, 2024 | 6.33 Mn |
| Mar 31, 2024 | 192,600.00 |
| Mar 31, 2024 | 192,600.00 |